GlassScriptPhysician profile
Kevin P Cavanaugh
NPI 1184938284
$19,597.39
in general payments reported to CMS, 2019-2025
34 companies · $6,402 in 2025
The $6,402 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,223 · 2020: $1,583 · 2021: $2,086 · 2022: $1,870 · 2023: $2,966 · 2024: $2,467 · 2025: $6,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,657 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,657.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Education | $178.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $3,257.56 | 2022-2025 | Emrosi |
| Abbvie INC. | $3,037.42 | 2019-2025 | Rinvoq, Botox, Skyrizi |
| Galderma Laboratories, L.P. | $2,221.29 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Janssen Biotech, INC. | $1,636.58 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $1,222.21 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,102.41 | 2019-2025 | Dupixent |
| Amgen INC. | $956.47 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $821.52 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Mayne Pharma Commercial LLC | $642.29 | 2019-2025 | |
| Allergan, INC. | $512.96 | 2019-2022 | |
| Revance Therapeutics, INC. | $480.57 | 2024-2025 | Daxxify |
| Dermavant Sciences, INC. | $443.30 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $394.49 | 2019-2025 | Ilumya |
| Genzyme Corporation | $297.23 | 2020-2025 | |
| Incyte Corporation | $278.89 | 2021-2025 | Opzelura |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $272.28 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $258.34 | 2019-2024 | |
| Ucb, INC. | $239.42 | 2023-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $236.65 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $236.29 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $218.03 | 2020-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $203.29 | 2019-2025 | Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.33 | 2023-2024 | Cyltezo |
| Musculoskeletal Transplant Foundation INC. | $139.71 | 2020 | |
| Sientra, INC. | $54.56 | 2019 | |
| Organon LLC | $40.71 | 2025 | Vtama, Nexplanon |
| Aclaris Therapeutics, INC. | $39.07 | 2019 | |
| Celgene Corporation | $36.19 | 2019 | |
| Smith+Nephew, INC. | $35.90 | 2019-2020 | |
| Almirall LLC | $32.11 | 2019-2021 | |
| Mission Pharmacal Company | $30.86 | 2019 | |
| Merz North America, INC. | $28.77 | 2024 | |
| Epi Health, LLC | $16.28 | 2020 | |
| Prugen, INC. Pharmaceuticals | $15.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Cavanaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.